Thuốc kháng giáp trạng

Optimizing Antithyroid Drug Duration in Graves’ Disease with Low TRAb: Evidence for Shorter Therapy

By MedXY 07/22/2026

A propensity-weighted analysis suggests that shorter antithyroid drug therapy (<12 months) in Graves' disease patients with low baseline TRAb is broadly comparable to the standard 12-18 months in preventing relapse, supporting individualized treatment duration.

Clinical Updates Diabetes & Endocrinology news Pediatrics

Evolving Paradigms in Pediatric Hyperthyroidism: A Two-Decade Review of Management and Outcomes

By MedXY 06/27/2026

This review synthesizes 20 years of data on pediatric hyperthyroidism, highlighting shifts toward prolonged antithyroid drug therapy, reduced definitive treatments, and rising relapse rates, underscoring the need for individualized long-term management.

Diabetes & Endocrinology news Pediatrics

FT3/FT4 Ratio Emerges as a Practical Predictor of Relapse After Antithyroid Drug Withdrawal in Children

By MedXY 04/01/2026

In pediatric autoimmune hyperthyroidism, a higher FT3/FT4 ratio predicted relapse after antithyroid drug withdrawal, especially when orbitopathy was present.